The American Journal of Cardiology®
Advanced SearchSave search
Roundtable discussion| Volume 102, ISSUE 1, P32-39, July 01, 2008

The Editor's Roundtable: Bare-Metal Stents Versus Drug-Eluting Stents—Indications and Complications

Published:June 03, 2008DOI:https://doi.org/10.1016/j.amjcard.2008.03.051
The Editor's Roundtable: Bare-Metal Stents Versus Drug-Eluting Stents—Indications and Complications
Previous ArticleComparison of Neointimal Coverage by Optical Coherence Tomography of a Sirolimus-Eluting Stent Versus a Bare-Metal Stent Three Months After Implantation
Next ArticleComparison of Waist Circumference Versus Body Mass Index in Diagnosing Metabolic Syndrome and Identifying Apparently Healthy Subjects at Increased Risk of Cardiovascular Disease
      This CME activity is supported by an educational grant from Cordis Cardiology, Miami Lakes, Florida.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Sigwart U.
        • Puel J.
        • Mirkovitch V.
        • Joffre F.
        • Kappenberger L.
        Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.
        N Engl J Med. 1987; 316: 701-706
        View in Article
        • Kaul S.
        • Shah P.K.
        • Diamond G.A.
        As time goes by.
        J Am Coll Cardiol. 2007; 50: 128-137
        View in Article
        • Assali A.R.
        • Moustapha A.
        • Sdringola S.
        • Denktas A.E.
        • Willerson J.T.
        • Holmes D.R.
        • Smalling R.W.
        Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial).
        Am J Cardiol. 2006; 98: 729-733
        View in Article
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.-A.
        • Steg P.G.
        • Morel M.
        • Mauri L.
        • Vranckx P.
        • et al.
        • Academic Research Consortium
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        View in Article
        • Steinhubl S.R.
        • Berger P.B.
        • Mann J.T.
        • CREDO Investigators
        Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention.
        JAMA. 2002; 288: 2411-2420
        View in Article
        • United States Food and Drug Administration
        FDA statement on coronary drug-eluting stents (September 14, 2006).
        http://www.fda.gov/cdrh/news/091406.html
        (Accessed November 10, 2007)
        View in Article

      Article Info

      Publication History

      Published online: June 03, 2008
      Accepted: March 28, 2008
      Received: March 28, 2008

      Footnotes

      This discussion took place at Baylor University Medical Center, Dallas, Texas, on September 6, 2007.

      Identification

      DOI: https://doi.org/10.1016/j.amjcard.2008.03.051

      Copyright

      © 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX